NCR1 and neoplasm: TriKCEs targeting more TAAs or co-engaging more NK cell activating receptors should exhibit better efficacy, as Innate Pharma’s TriKCEs targeting both NKp46 and CD16 have shown with potent in vivo tumor killing activity that appeared superior to those of therapeutic antibodies [149].